A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy

Overview of attention for article published in Journal of Medical Economics, December 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

policy: 1 policy source

twitter: 1 X user

Readers on

mendeley: 50 Mendeley

So far, Altmetric has seen 1 policy document that references this research output.

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence (NICE) on 30 Jun 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.